BRPI0918476B8 - compostos dímeros de pirrolobenzodiazepina assimétricos e uso dos mesmos para tratar uma doença proliferativa - Google Patents
compostos dímeros de pirrolobenzodiazepina assimétricos e uso dos mesmos para tratar uma doença proliferativaInfo
- Publication number
- BRPI0918476B8 BRPI0918476B8 BRPI0918476A BRPI0918476A BRPI0918476B8 BR PI0918476 B8 BRPI0918476 B8 BR PI0918476B8 BR PI0918476 A BRPI0918476 A BR PI0918476A BR PI0918476 A BRPI0918476 A BR PI0918476A BR PI0918476 B8 BRPI0918476 B8 BR PI0918476B8
- Authority
- BR
- Brazil
- Prior art keywords
- asymmetric
- group
- treat
- formula
- proliferative disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
dímeros de pirrolobenzodiazepina assimétricos para o tratamento de doenças proliferativas. reivindicam-se dímeros de pirrolobenzodiazepina (dímeros de pbd) assimétricos de fórmula (i), que são assimétricos devido pelos menos aos valores que as variáveis r12 e r2 representam. fómula (i), onde r2 é de fórmula (ii), onde a é um grupo arila de c5-7, x é selecionado a partir do grupo que compreende: oh, sh, co2h, coh, n=c=o nhrn, onde rn é selecionado a partir do grupo que compreende h e alquila de c1-4, e (oc2h4)moch3, onde m é 1 a 3, e:-z-(ch2)n-, onde z é selecionado a partir de uma ligação simples, o, s e nh e n é de 1 a 3; ou (ii) q1 é -ch=ch-, e q2 é uma ligação simples; r12 é um grupo arila de c5-10, opcionalmente substituído por um ou mais substituintes selecionados a partir do grupo que compreende: halo, nitro, ciano, éter, alquila de c1-7, heterociclila de c3-7 e bis-óxi-alquileno de c1-3. as outras variáveis são como definidas nas reivindicações. os compostos são úteis para o tratamento de doenças proliferativas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0819095.1 | 2008-10-17 | ||
GBGB0819095.1A GB0819095D0 (en) | 2008-10-17 | 2008-10-17 | Pyrrolobenzodiazepines |
PCT/GB2009/002498 WO2010043880A1 (en) | 2008-10-17 | 2009-10-16 | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0918476A2 BRPI0918476A2 (pt) | 2015-12-01 |
BRPI0918476B1 BRPI0918476B1 (pt) | 2021-04-06 |
BRPI0918476B8 true BRPI0918476B8 (pt) | 2021-05-25 |
Family
ID=40097621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0918476A BRPI0918476B8 (pt) | 2008-10-17 | 2009-10-16 | compostos dímeros de pirrolobenzodiazepina assimétricos e uso dos mesmos para tratar uma doença proliferativa |
Country Status (24)
Country | Link |
---|---|
US (3) | US8592576B2 (pt) |
EP (1) | EP2350080B1 (pt) |
JP (2) | JP5995441B2 (pt) |
KR (1) | KR101755722B1 (pt) |
CN (3) | CN105732665B (pt) |
AU (1) | AU2009305190B2 (pt) |
BR (1) | BRPI0918476B8 (pt) |
CA (1) | CA2735477C (pt) |
CY (1) | CY1117106T1 (pt) |
DK (1) | DK2350080T3 (pt) |
ES (1) | ES2557283T3 (pt) |
GB (1) | GB0819095D0 (pt) |
HK (1) | HK1154575A1 (pt) |
HR (1) | HRP20160003T1 (pt) |
HU (1) | HUE025905T2 (pt) |
IL (1) | IL211985A (pt) |
MX (1) | MX2011003342A (pt) |
NZ (1) | NZ591425A (pt) |
PL (1) | PL2350080T3 (pt) |
PT (1) | PT2350080E (pt) |
SI (1) | SI2350080T1 (pt) |
SM (1) | SMT201600017B (pt) |
WO (1) | WO2010043880A1 (pt) |
ZA (1) | ZA201101425B (pt) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006006199D1 (de) | 2005-10-05 | 2009-05-20 | Spirogen Ltd | 4-ä4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo ä2, 1-cüä1,4übenzodiazepin-8-yloxy)-butyrylaminoü-1h-pyrrol-2-carbonsäurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung |
GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
MX2011008328A (es) | 2009-02-05 | 2011-11-04 | Immunogen Inc | Derivados novedosos de benzodiacepina. |
JP5870400B2 (ja) * | 2010-04-15 | 2016-03-01 | シアトル ジェネティクス,インコーポレーテッド | 標的化ピロロベンゾジアゼピンコンジュゲート |
EP2789622B1 (en) * | 2010-04-15 | 2017-03-01 | MedImmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
MX346635B (es) | 2011-02-15 | 2017-03-27 | Immunogen Inc | Derivados citotoxicos de la benzodiazepina. |
DK2707031T3 (da) | 2011-05-08 | 2019-10-07 | Legochem Biosciences Inc | Protein-active agent conjugates and method for preparing the same |
CN103987718A (zh) * | 2011-09-20 | 2014-08-13 | 斯皮罗根有限公司 | 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓 |
JP6166728B2 (ja) * | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
ES2687246T3 (es) * | 2011-10-14 | 2018-10-24 | Seattle Genetics, Inc. | Pirrolobenzodiazepinas y conjugados dirigidos |
EP2753178B1 (en) * | 2011-10-14 | 2017-12-06 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
SG11201401021TA (en) | 2011-10-14 | 2014-08-28 | Spirogen Sarl | Pyrrolobenzodiazepines |
EP2751110B1 (en) * | 2011-10-14 | 2017-04-19 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases |
KR101960130B1 (ko) | 2012-04-30 | 2019-03-19 | 메디뮨 리미티드 | 피롤로벤조디아제핀 |
JP6157596B2 (ja) | 2012-04-30 | 2017-07-05 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン |
US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
CN102757435B (zh) * | 2012-06-21 | 2014-05-28 | 成都苑东药业有限公司 | 一种反式-3-吲哚基-4-吲哚并二氮杂卓环庚烷基-2,5-吡咯烷-2,5-二酮化合物及其制备方法 |
CA2885305C (en) | 2012-10-12 | 2019-11-12 | Spirogen Sarl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
CA2941485C (en) | 2012-10-12 | 2018-06-12 | Philip Wilson Howard | Pyrrolobenzodiazepines and conjugates thereof |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
SI2906298T1 (sl) | 2012-10-12 | 2018-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
LT2906252T (lt) * | 2012-10-12 | 2017-09-11 | Adc Therapeutics Sa | Pirolobenzodiazepino-anti-her2 antikūno konjugatai |
TR201902494T4 (tr) | 2012-10-12 | 2019-03-21 | Medimmune Ltd | Pirrolobenzodiazepinler ve onların konjugatları. |
BR112015008238A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolbenzodiazepina-anticorpo anti-cd22 |
WO2014057113A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
JP6392764B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa | ピロロベンゾジアゼピン−抗体結合体 |
CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
JP6527466B2 (ja) * | 2012-12-21 | 2019-06-05 | メドイミューン・リミテッドMedImmune Limited | 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体 |
DK2968494T3 (en) | 2013-03-13 | 2019-03-04 | Seattle Genetics Inc | ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs |
SG10202009046SA (en) | 2013-03-13 | 2020-10-29 | Seattle Genetics Inc | Cyclodextrin and antibody-drug conjugate formulations |
SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
AU2014318545A1 (en) | 2013-09-12 | 2016-03-24 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
GB201407816D0 (en) * | 2014-05-02 | 2014-06-18 | King S College London | Pyrrolobenzodiazepine Compounds |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CN114106185A (zh) | 2014-09-12 | 2022-03-01 | 基因泰克公司 | 抗her2抗体和免疫缀合物 |
AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
TW201632532A (zh) | 2015-01-14 | 2016-09-16 | 必治妥美雅史谷比公司 | 伸雜芳基-橋聯苯并二氮呯二聚體,其共軛物及製造及使用方法 |
BR112017014599A2 (pt) | 2015-01-14 | 2018-01-16 | Bristol-Myers Squibb Company | dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso |
US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201510010D0 (en) | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
AU2016284340A1 (en) | 2015-06-23 | 2018-02-08 | Bristol-Myers Squibb Company | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses |
LT3325483T (lt) | 2015-07-21 | 2020-01-27 | Immunogen, Inc. | Citotoksinių benzodiazepino darinių gavimo būdai |
GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
US20180339985A1 (en) | 2015-08-21 | 2018-11-29 | Femtogenix Limited | Pdd compounds |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) * | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2018053552A2 (en) * | 2016-09-19 | 2018-03-22 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
EP3544983A2 (en) | 2016-11-23 | 2019-10-02 | Immunogen, Inc. | Selective sulfonation of benzodiazepine derivatives |
PT3558391T (pt) | 2016-12-23 | 2022-05-05 | Immunogen Inc | Imunoconjugados direcionados para adam9 e respetivos métodos de utilização |
TW201825515A (zh) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met抗體以及其免疫結合物及用途 |
LT3544636T (lt) | 2017-02-08 | 2021-06-25 | Adc Therapeutics Sa | Pirolobenzodiazepino-antikūno konjugatai |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
HUE059828T2 (hu) | 2017-04-18 | 2023-01-28 | Medimmune Ltd | Pirrolobenzodiazepin konjugátumok |
EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
AU2018316532B2 (en) | 2017-08-18 | 2022-11-24 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
EP3690038A4 (en) | 2017-09-29 | 2021-05-19 | Daiichi Sankyo Company, Limited | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
JP2021502969A (ja) * | 2017-11-14 | 2021-02-04 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン複合体 |
MA51184A (fr) | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CA3100141A1 (en) | 2018-05-29 | 2019-12-05 | Intocell, Inc. | Novel benzodiazepine derivatives and uses thereof |
TW202029980A (zh) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途 |
GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3523941A (en) * | 1967-03-06 | 1970-08-11 | Hoffmann La Roche | Benzodiazepine compounds and process for their preparation |
US3524849A (en) * | 1967-10-27 | 1970-08-18 | Hoffmann La Roche | Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein |
IL33558A (en) | 1968-12-30 | 1973-10-25 | Fujisawa Pharmaceutical Co | Antibiotic pyrrolo-benzodiazepine compound,its derivatives and processes for their production |
FR2027356A1 (en) | 1968-12-30 | 1970-09-25 | Fujisawa Pharmaceutical Co | Benzodiazepinone antibiotics |
JPS6053033B2 (ja) | 1976-12-28 | 1985-11-22 | 財団法人微生物化学研究会 | 新制癌抗生物質マゼスラマイシン及びその製造方法 |
JPS585916B2 (ja) * | 1977-12-27 | 1983-02-02 | 株式会社ミドリ十字 | 新規ベンゾジアゼピン系化合物 |
JPS5615289A (en) * | 1979-07-17 | 1981-02-14 | Green Cross Corp:The | Novel benzodiazepinnbased compound 3 |
JPS57131791A (en) | 1980-12-31 | 1982-08-14 | Fujisawa Pharmaceut Co Ltd | Benzodiazepine derivative and its preparation |
JPS58180487A (ja) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 抗生物質dc−81およびその製造法 |
FR2586683B1 (fr) | 1985-08-29 | 1988-07-01 | Centre Nat Rech Scient | Nouveaux derives de neothramycine, leur procede de preparation et leur application en tant que medicaments |
FR2676230B1 (fr) | 1991-05-07 | 1993-08-27 | Centre Nat Rech Scient | Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant. |
GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
FR2696176B1 (fr) * | 1992-09-28 | 1994-11-10 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
GB9818731D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
DE69930328T2 (de) | 1998-08-27 | 2006-12-14 | Spirogen Ltd., Ryde | Dimere Pyrrolobenzodiazepine |
GB9818730D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
DK1320522T3 (da) | 2000-09-19 | 2006-04-03 | Moses Lee | Achirale analoger af CC-1065 og af duocarmyciner samt præparater og metoder til anvendelse deraf |
US6660856B2 (en) | 2002-03-08 | 2003-12-09 | Kaohsiung Medical University | Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues |
US20040138269A1 (en) * | 2002-10-11 | 2004-07-15 | Sugen, Inc. | Substituted pyrroles as kinase inhibitors |
GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
EP1608664B1 (en) * | 2003-03-31 | 2009-01-28 | Council of Scientific and Industrial Research | Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof |
GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
EP1675857B1 (en) | 2003-10-22 | 2011-07-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
GB0404578D0 (en) * | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
US7741319B2 (en) | 2004-03-01 | 2010-06-22 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
GB0404574D0 (en) * | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Amino acids |
GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
US7528126B2 (en) * | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
PT1879901E (pt) * | 2005-04-21 | 2010-03-29 | Spirogen Ltd | Pirrolobenzodiazepinas |
GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
US20070154906A1 (en) | 2005-10-05 | 2007-07-05 | Spirogen Ltd. | Methods to identify therapeutic candidates |
DE602006006199D1 (de) * | 2005-10-05 | 2009-05-20 | Spirogen Ltd | 4-ä4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo ä2, 1-cüä1,4übenzodiazepin-8-yloxy)-butyrylaminoü-1h-pyrrol-2-carbonsäurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung |
WO2008050140A2 (en) | 2006-10-27 | 2008-05-02 | Spirogen Limited | Compounds for treatment of parasitic infection |
GB0722088D0 (en) | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0722087D0 (en) | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Polyamides |
GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819097D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
EP2789622B1 (en) | 2010-04-15 | 2017-03-01 | MedImmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
JP5870400B2 (ja) | 2010-04-15 | 2016-03-01 | シアトル ジェネティクス,インコーポレーテッド | 標的化ピロロベンゾジアゼピンコンジュゲート |
GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
CN103987718A (zh) | 2011-09-20 | 2014-08-13 | 斯皮罗根有限公司 | 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓 |
EP2753178B1 (en) | 2011-10-14 | 2017-12-06 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
SG11201401021TA (en) | 2011-10-14 | 2014-08-28 | Spirogen Sarl | Pyrrolobenzodiazepines |
EP2751110B1 (en) | 2011-10-14 | 2017-04-19 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases |
JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
CN103987407B (zh) | 2011-10-14 | 2016-08-24 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其偶联物 |
ES2687246T3 (es) | 2011-10-14 | 2018-10-24 | Seattle Genetics, Inc. | Pirrolobenzodiazepinas y conjugados dirigidos |
JP6157596B2 (ja) | 2012-04-30 | 2017-07-05 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン |
KR101960130B1 (ko) | 2012-04-30 | 2019-03-19 | 메디뮨 리미티드 | 피롤로벤조디아제핀 |
EP2869850B1 (en) | 2012-07-09 | 2017-08-23 | Genentech, Inc. | Immunoconjugates comprising anti-cd79b antibodies |
EP2869849A1 (en) | 2012-07-09 | 2015-05-13 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
US9464141B2 (en) | 2012-08-02 | 2016-10-11 | Genentech, Inc. | Anti-ETBR antibodies and immunoconjugates |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
CA2941485C (en) | 2012-10-12 | 2018-06-12 | Philip Wilson Howard | Pyrrolobenzodiazepines and conjugates thereof |
SI2906298T1 (sl) | 2012-10-12 | 2018-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
TR201902494T4 (tr) | 2012-10-12 | 2019-03-21 | Medimmune Ltd | Pirrolobenzodiazepinler ve onların konjugatları. |
LT2906252T (lt) | 2012-10-12 | 2017-09-11 | Adc Therapeutics Sa | Pirolobenzodiazepino-anti-her2 antikūno konjugatai |
JP6392764B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa | ピロロベンゾジアゼピン−抗体結合体 |
WO2014057118A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
CA2885305C (en) | 2012-10-12 | 2019-11-12 | Spirogen Sarl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
WO2014057113A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
BR112015008238A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolbenzodiazepina-anticorpo anti-cd22 |
JP6527466B2 (ja) | 2012-12-21 | 2019-06-05 | メドイミューン・リミテッドMedImmune Limited | 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体 |
CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
LT2958944T (lt) | 2013-02-22 | 2019-07-10 | Abbvie Stemcentrx Llc | Antikūno prieš dll3 ir pbd konjugatai bei jų panaudojimas |
SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP2968585B1 (en) | 2013-03-13 | 2018-07-18 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
WO2014174111A1 (en) | 2013-04-26 | 2014-10-30 | Pierre Fabre Medicament | Axl antibody-drug conjugate and its use for the treatment of cancer |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US20160256561A1 (en) | 2013-10-11 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
KR102337414B1 (ko) | 2013-12-16 | 2021-12-10 | 제넨테크, 인크. | 펩타이드 모방체 화합물 및 이의 항체-약물 컨쥬게이트 |
GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
-
2008
- 2008-10-17 GB GBGB0819095.1A patent/GB0819095D0/en not_active Ceased
-
2009
- 2009-10-16 US US13/123,327 patent/US8592576B2/en active Active
- 2009-10-16 SI SI200931333T patent/SI2350080T1/sl unknown
- 2009-10-16 MX MX2011003342A patent/MX2011003342A/es active IP Right Grant
- 2009-10-16 WO PCT/GB2009/002498 patent/WO2010043880A1/en active Application Filing
- 2009-10-16 CN CN201610092115.7A patent/CN105732665B/zh active Active
- 2009-10-16 ES ES09740185.5T patent/ES2557283T3/es active Active
- 2009-10-16 JP JP2011531560A patent/JP5995441B2/ja active Active
- 2009-10-16 CN CN201610094457.2A patent/CN105732666B/zh active Active
- 2009-10-16 EP EP09740185.5A patent/EP2350080B1/en active Active
- 2009-10-16 PL PL09740185T patent/PL2350080T3/pl unknown
- 2009-10-16 BR BRPI0918476A patent/BRPI0918476B8/pt active IP Right Grant
- 2009-10-16 KR KR1020117008832A patent/KR101755722B1/ko active IP Right Grant
- 2009-10-16 HU HUE09740185A patent/HUE025905T2/en unknown
- 2009-10-16 CN CN2009801411484A patent/CN102186855A/zh active Pending
- 2009-10-16 NZ NZ591425A patent/NZ591425A/xx unknown
- 2009-10-16 PT PT97401855T patent/PT2350080E/pt unknown
- 2009-10-16 AU AU2009305190A patent/AU2009305190B2/en active Active
- 2009-10-16 DK DK09740185.5T patent/DK2350080T3/en active
- 2009-10-16 CA CA2735477A patent/CA2735477C/en active Active
-
2011
- 2011-02-23 ZA ZA2011/01425A patent/ZA201101425B/en unknown
- 2011-03-29 IL IL211985A patent/IL211985A/en active IP Right Grant
- 2011-08-19 HK HK11108770.6A patent/HK1154575A1/zh unknown
-
2013
- 2013-11-13 US US14/079,113 patent/US8940733B2/en active Active
-
2014
- 2014-12-22 US US14/579,094 patent/US9624227B2/en active Active
-
2015
- 2015-04-16 JP JP2015084175A patent/JP2015166354A/ja active Pending
-
2016
- 2016-01-04 HR HRP20160003TT patent/HRP20160003T1/hr unknown
- 2016-01-11 CY CY20161100019T patent/CY1117106T1/el unknown
- 2016-01-15 SM SM201600017T patent/SMT201600017B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0918476B8 (pt) | compostos dímeros de pirrolobenzodiazepina assimétricos e uso dos mesmos para tratar uma doença proliferativa | |
EA200971074A1 (ru) | Антивирусные соединения | |
CY1121357T1 (el) | Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις | |
BR112014013661A2 (pt) | Derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
EA201170161A1 (ru) | 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы | |
EA200970666A1 (ru) | Трициклические соединения, композиции и способы | |
EA201591382A1 (ru) | Ингибиторы гистондеметилаз | |
EA201891553A1 (ru) | Ингибиторы syk | |
EA201490853A1 (ru) | Противовирусные соединения | |
EA201490132A1 (ru) | Противовирусные соединения | |
EA201791916A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
EA201490396A1 (ru) | Ингибиторы репликации вирусов гриппа | |
EA201790882A1 (ru) | Способы и композиции для терапии рака печени | |
EA201100879A1 (ru) | Производные пиридопиримидина в качестве ингибиторов аутотаксина | |
CL2011000134A1 (es) | Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer. | |
BR112012023660A2 (pt) | novos métodos para direcionar células-tronco cancerosas | |
EA201491747A1 (ru) | Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов | |
EA200971141A1 (ru) | Соединения, активирующие теломеразу, и способы их применения | |
BR112012024712A2 (pt) | antagonistas do receptor vaniloide trpv1 com uma porção bicíclica | |
DK1885187T3 (da) | Fremgangsmåde til behandling af lægemiddelresistent cancer | |
BR112013028486A2 (pt) | método para promover crescimento de planta | |
EA201690972A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
EA201891379A1 (ru) | Ингибиторы тирозинкиназы брутона и способы их применения | |
BR112012017994A2 (pt) | composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: SPIROGEN DEVELOPMENTS SARL (GB) |
|
B25A | Requested transfer of rights approved |
Owner name: SPIROGEN SARL (CH) |
|
B25A | Requested transfer of rights approved |
Owner name: MEDIMMUNE LIMITED (GB) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |